Another 20 patients with active SLE were recruited to participate in a 12-week pilot clinical trial of orally encapsulated FMT; after the FMT therapy, both serum anti-dsDNA antibody levels and the SLEDAI score were significantly reduced; furthermore, in addition to an increased synthesis of SCFAs in the gut and decreased levels of IL-6 and the CD4+ memory/naive ratio in peripheral blood, there was an enrichment of beneficial SCFA-producing bacterial taxa and a reduction in inflammation-related bacterial taxa; no deaths or serious adverse events were reported[15]. This evidence concerns the gene CD4 and systemic lupus erythematosus.